Home / Stocks / KROS

KROS insider trading

Keros Therapeutics, Inc. — open-market insider buys and $1M+ sells from SEC Forms 3, 4 and 5.
Insider buys · 24 mo
7
Bought · 24 mo
$9.5M
Buys · last 90 days
3 · $31k
Most recent buy
2026-08-19

Recent insider filings

FiledInsiderTypeSharesPriceValue
2026-08-19BIENAIME JEAN JACQUES
Director
Bought1,000$10.27$10k
2026-07-17BIENAIME JEAN JACQUES
Director
Bought1,000$10.61$11k
2026-06-17BIENAIME JEAN JACQUES
Director
Bought1,000$10.19$10k
2026-05-19BIENAIME JEAN JACQUES
Director
Bought1,000$10.58$11k
2026-04-17BIENAIME JEAN JACQUES
Director
Bought1,000$11.70$12k
2026-03-11BIENAIME JEAN JACQUES
Director
Bought2,000$11.21$22k
2025-10-17Kariv Tomer
Director · 10% owner
Sold4,787,331$17.75$85.0M
2025-10-15ADAR1 Capital Management GP, LLC
10% owner
Sold5,389,264$17.75$95.7M
2025-04-11ADAR1 Capital Management GP, LLC
10% owner
Bought934,258$10.13$9.5M
2025-01-24Regnante Keith
CHIEF FINANCIAL OFFICER
Sold40,000$45.29$1.8M

Most active insider buyers

InsiderRoleBuysTotal bought
ADAR1 Capital Management GP, LLC10% owner1$9.5M
BIENAIME JEAN JACQUESDirector6$76k

See KROS on the chart

Every insider buy and sell for KROS plotted on the price, the full two-year history, cluster scores and daily updates — in the members area, $29/month. A free quarterly sample of the whole dataset needs no account.

Open the browserFree sample
Data from the SEC EDGAR ownership filings, refreshed daily. Only open-market purchases (transaction code P) and sales of $1M or more are shown; grants, option exercises and tax withholding are excluded because they run on schedules set years earlier. Not investment advice.